Larimar Therapeutics, Inc. (LRMR)
LRMRNASDAQ-GMBiotechnology: Pharmaceutical Preparations
$2.73
-0.0200 (-0.73%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $2.81 +3.08%
- Market cap
- $292.35m
- P/E
- –
- EPS, last 4 quarters
- $-1.95
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.92 to $6.42
- Average volume
- –
- Previous close
- $2.75
Analysts
2 coveringBuy2 buy, 0 hold, 0 sell
Targets a year out average $16.00, +486.1% from here
Earnings
next estimate $-0.3500Next report Nov 18, 2026
Sep 2025
-56.4%
Dec 2025
-65.9%
Mar 2026
+41.5%
Jun 2026
+23.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$49.50m | -$64.02m | -$60.73m | -$4.74m |
| Net income | -$47.71m | -$62.50m | -$59.23m | -$3.17m |
News
8 latest- Larimar Therapeutics, Inc. Completes Rolling BLA Submission for Nomlabofusp and Reports Preliminary Cash of $128.7 millionFintel · 2 days ago
- Tuesday Sector Leaders: Biotechnology, Drugs BNK Invest · Oct 20, 2026
- 3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts AheadMarketBeat · Oct 10, 2026
- Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks · Oct 5, 2026
- Larimar Therapeutics Names John Harlow As President And COO RTTNews · Sep 30, 2026
- 5 Small Drug Stocks Poised to Benefit From a Biotech RecoveryZacks · Sep 14, 2026
- Thursday 7/9 Insider Buying Report: LRMR, EVMNBNK Invest · Jul 9, 2026
- Larimar Submits First Module Of BLA For Nomlabofusp, Reports Positive Long-Term FA Data RTTNews · Jun 29, 2026
The company
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar's lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GM
- Region
- North America
- Website
- larimartx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.